Relief Therapeutics Holding AG (RLF.SW)
CHF 4.1
(-6.82%)
CHF 4.1
(-6.82%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -108.2 Million CHF | 49.26% |
| 2022 | -50.26 Million CHF | 1.47% |
| 2021 | -32.69 Million CHF | -71.9% |
| 2020 | -6.09 Million CHF | -1939.96% |
| 2019 | -946 Thousand CHF | -95.86% |
| 2018 | -255 Thousand CHF | 61.11% |
| 2017 | -1.73 Million CHF | 44.68% |
| 2016 | -16.48 Million CHF | -5.13% |
| 2015 | -81 Thousand CHF | 64.54% |
| 2014 | -6.02 Million CHF | 39.28% |
| 2013 | -9.87 Million CHF | -54.77% |
| 2012 | 478.1 Thousand CHF | 88.74% |
| 2011 | -57.12 Million CHF | -269.81% |
| 2010 | -15.38 Million CHF | -87.83% |
| 2009 | -8.18 Million CHF | -64.55% |
| 2008 | -4.97 Million CHF | -319.19% |
| 2007 | 1.64 Million CHF | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.61 Million CHF | 0.0% |
| 2023 Q2 | -9.94 Million CHF | 0.0% |
| 2023 FY | - CHF | 49.26% |
| 2023 Q4 | -6.64 Million CHF | 0.0% |
| 2022 FY | - CHF | 1.47% |
| 2022 Q2 | -18.93 Million CHF | 0.0% |
| 2022 Q4 | -13.75 Million CHF | 0.0% |
| 2021 Q2 | 687 Thousand CHF | 0.0% |
| 2021 Q4 | -32.38 Million CHF | 0.0% |
| 2021 FY | - CHF | -71.9% |
| 2020 Q2 | -3.5 Million CHF | 0.0% |
| 2020 FY | - CHF | -1939.96% |
| 2020 Q4 | -15.79 Million CHF | 0.0% |
| 2019 Q2 | -420 Thousand CHF | 0.0% |
| 2019 FY | - CHF | -95.86% |
| 2019 Q4 | -526 Thousand CHF | 0.0% |
| 2018 Q2 | -420 Thousand CHF | 0.0% |
| 2018 Q4 | -63 Thousand CHF | 0.0% |
| 2018 FY | - CHF | 61.11% |
| 2017 FY | - CHF | 44.68% |
| 2017 Q4 | -685 Thousand CHF | 0.0% |
| 2017 Q2 | -1.04 Million CHF | 0.0% |
| 2016 Q1 | -4.2 Million CHF | 0.0% |
| 2016 FY | - CHF | -5.13% |
| 2016 Q2 | -2000.00 CHF | 99.95% |
| 2016 Q4 | -1.92 Million CHF | 0.0% |
| 2015 Q3 | -1.75 Million CHF | 0.0% |
| 2015 FY | - CHF | 64.54% |
| 2015 Q1 | -1.75 Million CHF | 0.0% |
| 2015 Q4 | -4.2 Million CHF | -139.66% |
| 2015 Q2 | -1.75 Million CHF | 0.0% |
| 2014 Q4 | -1.75 Million CHF | 30.78% |
| 2014 FY | - CHF | 39.28% |
| 2014 Q3 | -2.53 Million CHF | 0.0% |
| 2014 Q2 | -2.53 Million CHF | 0.0% |
| 2014 Q1 | -2.53 Million CHF | 0.0% |
| 2013 Q4 | -2.53 Million CHF | 2.75% |
| 2013 Q3 | -2.6 Million CHF | 0.0% |
| 2013 Q2 | -2.6 Million CHF | 0.0% |
| 2013 Q1 | -2.6 Million CHF | 0.0% |
| 2013 FY | - CHF | -54.77% |
| 2012 FY | - CHF | 88.74% |
| 2012 Q4 | -2.6 Million CHF | -68.84% |
| 2012 Q2 | -1.54 Million CHF | 0.0% |
| 2012 Q1 | -1.54 Million CHF | 0.0% |
| 2012 Q3 | -1.54 Million CHF | 0.0% |
| 2011 Q2 | -14.21 Million CHF | 0.0% |
| 2011 Q4 | -1.54 Million CHF | 89.16% |
| 2011 FY | - CHF | -269.81% |
| 2011 Q3 | -14.21 Million CHF | 0.0% |
| 2011 Q1 | -14.21 Million CHF | 0.0% |
| 2010 Q1 | -3.84 Million CHF | 0.0% |
| 2010 Q4 | -14.21 Million CHF | -269.81% |
| 2010 Q3 | -3.84 Million CHF | 0.0% |
| 2010 Q2 | -3.84 Million CHF | 0.0% |
| 2010 FY | - CHF | -87.83% |
| 2009 Q2 | -2.04 Million CHF | 0.0% |
| 2009 Q3 | -2.04 Million CHF | 0.0% |
| 2009 Q4 | -3.84 Million CHF | -87.83% |
| 2009 FY | - CHF | -64.55% |
| 2009 Q1 | -2.04 Million CHF | 0.0% |
| 2008 Q4 | -2.04 Million CHF | -64.55% |
| 2008 Q2 | -1.24 Million CHF | 0.0% |
| 2008 Q1 | -1.24 Million CHF | 0.0% |
| 2008 FY | - CHF | -319.19% |
| 2008 Q3 | -1.24 Million CHF | 0.0% |
| 2007 FY | - CHF | 0.0% |
| 2007 Q3 | 567.62 Thousand CHF | 0.0% |
| 2007 Q2 | 567.62 Thousand CHF | 0.0% |
| 2007 Q1 | 567.62 Thousand CHF | 0.0% |
| 2007 Q4 | -1.24 Million CHF | -319.19% |
| 2006 Q4 | 567.62 Thousand CHF | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.22 Million CHF | -957.831% |
| BB Biotech AG | -201.25 Million CHF | 46.237% |
| Basilea Pharmaceutica AG | 29.49 Million CHF | 466.849% |
| Evolva Holding SA | -98.35 Million CHF | -10.009% |
| Idorsia Ltd | -254.55 Million CHF | 57.493% |
| Kuros Biosciences AG | -10.4 Million CHF | -939.504% |
| Molecular Partners AG | -59.51 Million CHF | -81.806% |
| Santhera Pharmaceuticals Holding AG | 79.17 Million CHF | 236.664% |